Coastwise Capital Group LLC Acquires 371 Shares of Merck & Co., Inc. (NYSE:MRK)

Coastwise Capital Group LLC raised its holdings in Merck & Co., Inc. (NYSE:MRKFree Report) by 8.9% during the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,537 shares of the company’s stock after buying an additional 371 shares during the period. Coastwise Capital Group LLC’s holdings in Merck & Co., Inc. were worth $495,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of MRK. Vermillion & White Wealth Management Group LLC acquired a new position in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $27,000. Bare Financial Services Inc acquired a new position in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $28,000. Burkett Financial Services LLC acquired a new position in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $28,000. Rakuten Securities Inc. acquired a new position in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $30,000. Finally, RIA Advisory Group LLC acquired a new position in shares of Merck & Co., Inc. in the fourth quarter valued at approximately $30,000. Institutional investors own 76.07% of the company’s stock.

Analyst Ratings Changes

MRK has been the topic of a number of analyst reports. TheStreet downgraded Merck & Co., Inc. from a “b+” rating to a “c+” rating in a research report on Monday, March 4th. Argus raised Merck & Co., Inc. to a “strong-buy” rating in a research report on Wednesday, June 5th. Societe Generale cut Merck & Co., Inc. from a “hold” rating to a “sell” rating and set a $104.00 target price for the company. in a research note on Monday, March 11th. Wells Fargo & Company upped their target price on Merck & Co., Inc. from $130.00 to $135.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 27th. Finally, Truist Financial upped their target price on Merck & Co., Inc. from $142.00 to $143.00 and gave the stock a “buy” rating in a research note on Friday, April 26th. One analyst has rated the stock with a sell rating, three have assigned a hold rating, eight have given a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $133.00.

Get Our Latest Analysis on MRK

Merck & Co., Inc. Price Performance

Shares of MRK traded up $0.35 during trading hours on Tuesday, reaching $131.84. The stock had a trading volume of 11,449,639 shares, compared to its average volume of 8,065,915. Merck & Co., Inc. has a 12 month low of $99.14 and a 12 month high of $133.10. The stock has a market capitalization of $333.93 billion, a PE ratio of 146.49, a PEG ratio of 2.52 and a beta of 0.39. The company has a debt-to-equity ratio of 0.77, a quick ratio of 0.99 and a current ratio of 1.25. The company’s 50-day moving average is $128.55 and its two-hundred day moving average is $122.03.

Merck & Co., Inc. (NYSE:MRKGet Free Report) last announced its earnings results on Thursday, April 25th. The company reported $2.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.94 by $0.13. The business had revenue of $15.78 billion during the quarter, compared to analyst estimates of $15.21 billion. Merck & Co., Inc. had a return on equity of 14.05% and a net margin of 3.76%. Merck & Co., Inc.’s revenue for the quarter was up 8.9% compared to the same quarter last year. During the same period last year, the company earned $1.40 EPS. Research analysts expect that Merck & Co., Inc. will post 8.64 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, July 8th. Investors of record on Monday, June 17th will be given a dividend of $0.77 per share. This represents a $3.08 annualized dividend and a yield of 2.34%. The ex-dividend date is Monday, June 17th. Merck & Co., Inc.’s dividend payout ratio is currently 342.22%.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes under the Keytruda, Bridion, Adempas, Lagevrio, Belsomra, Simponi, and Januvia brands, as well as vaccine products consisting of preventive pediatric, adolescent, and adult vaccines under the Gardasil/Gardasil 9, ProQuad, M-M-R II, Varivax, RotaTeq, Live Oral, Vaxneuvance, Pneumovax 23, and Vaqta names.

Featured Articles

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKFree Report).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.